NY0123
NY0123 is a EPAC1 inhibitor. NY0123 significantly inhibits the expression of EPAC1, phosphorylated AKT, phosphorylated ERK1/2 and phosphorylated VEGFR2. NY0123 inhibits angiogenesis and tumor growth of triple-negative breast cancer. NY0123 is applicable to relevant research on triple-negative breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1801911-70-5
- Formule: C16H13Cl3N4O2
- Masse moléculaire:399.66
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform VEGFR
More
Activité biologique
Description
IC50 & Target
[1]|
VEGFR2 |
ERK1 |
ERK2 |
EPAC1 |
In Vivo
NY0123 (25-100 μM; topical application to CAM; single dose; 48-hour incubation) significantly suppresses angiogenesis in Gallus gallus domesticus embryo CAM models with greater efficacy than ESI-09[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 5-6 weeks old, 4T1 cell xenograft model)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every two days; 14 days
-
Result:Significantly reduced tumor volume and tumor weight compared to DMSO control.
Significantly lowered tumor microvessel density (measured via CD31 IHC staining) and tumor cell proliferation index (measured via Ki67 IHC staining) compared to DMSO control.
Exhibited greater inhibitory effects on tumor volume, tumor weight, MVD, and proliferation index than ESI-09.
Showed no treatment-related organ toxicities via H&E staining of heart, liver, lung, brain, spleen, kidney, and intestine tissues.
-
Animal Model:White leghorn (7-day-old embryo, CAM vascularization model)[1]
-
Dosage:25 μM, 50 μM, 100 μM
-
Administration:topical application to CAM; single dose; 48-hour incubation
-
Result:Significantly reduced CAM microvessel density at 100 μM compared to DMSO control.
Exhibited greater inhibitory effects on angiogenesis at 100 μM than ESI-09 at the same concentration.
Chemical Information
-
CAS No. 1801911-70-5
-
Masse moléculaire 399.66
-
Formule C16H13Cl3N4O2
-
SMILES
N#CC(=NNC1=CC(Cl)=C(Cl)C(Cl)=C1)C(=O)C2=NOC(=C2)C(C)(C)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NY0123 Related Classifications
HY-123795 Related Classifications
Powered by Bioz